Health Care • Biotechnology: Pharmaceutical Preparations
$93.44 ▲ +0.87
(+0.94%)
MKT CAP: $6.37B • VOL: 2.00M
52W L $75 52W H $122
RYTM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $189.8M | $130.1M | $77.4M |
| YoY Revenue Growth % | +45.8% | +68.1% | — |
| Gross Profit | $170.3M | $116.8M | — |
| Gross Margin % | 89.7% | 89.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$192.0M | -$265.5M | -$184.4M |
| Operating Margin % | -101.2% | -204.0% | -238.1% |
| Net Income (GAAP) | -$196.5K | -$260.6K | -$184.7K |
| EBITDA (Normalized) | -$191.3M | -$265.5M | -$181.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$115.7M | -$113.9M | -$136.2M |
| Capital Expenditures (CapEx) | $953.0K | $0 | $3.5M |
| Free Cash Flow (FCF) | -$116.6M | -$113.9M | -$139.6M |
| FCF Margin % | -61.5% | -87.5% | -180.3% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -6.8% |
| Cash & Short-Term Equivalents | $54.3M | $89.1M | — |
| Total Debt (Short + Long Term) | $100.9M | $108.3M | $824.7M |
| Total Stockholders' Equity | $139.1M | $21.7M | $1.69B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RYTM.